Li Wensong, Zhou Zicheng and Zhang Runfeng*
Volume3-Issue10
Dates: Received: 2022-10-15 | Accepted: 2022-10-25 | Published: 2022-10-26
Pages: 1240-1243
Abstract
Objective:
To observe the effect of Fastigial Nucleus Stimulation (FNS) on serum inflammatory
factors in patients with coronary heart disease.
Methods: 144 patients with coronary heart disease were randomly divided into the experimental group (n = 72) and the control group (n = 72). The control group received conventional medication for coronary heart disease. The experimental group was given the cerebellar nucleus electrical stimulation on the basis of routine medication. High-sensitivity C-reactive protein (hs-CRP), Interleukin-6 (IL-6), Tumor Necrosis Factor α (TNF-α), Lipoprotein-associated phospholipase A2 (Lp-PLA2) were measured before and after treatment in both groups.
Results: There were no significant differences in serum hs-CRP, TNF-α, IL-6 and Lp-PLA2 between the two groups before treatment (p > 0.05). After treatment, serum hs-CRP, TNF-α, IL-6 and Lp-PLA2 were significantly lower in the two groups than before treatment (p < 0.01). The levels of serum hs-CRP, TNF- α , IL-6 and Lp-PLA2 in the experimental group were significantly lower than those in the control group (p < 0.05).
Conclusion: FNS can effectively reduce the level of serum inflammatory factors in patients with coronary heart disease. (Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT04121715).
FullText HTML
FullText PDF
DOI: 10.37871/jbres1584
Certificate of Publication
Copyright
© 2022 Wensong L, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Wensong L, Zicheng Z, Runfeng Z. Effect of Fastigial Nucleus Stimulation on Serum Inflammatory Factors in Patients with Coronary Heart Disease. 2022 Oct 26; 3(10): 1240-1243. doi: 10.37871/jbres1584, Article ID: JBRES1584, Available at: https://www.jelsciences.com/articles/jbres1584.pdf
Subject area(s)
References
- De Stefano A, Mannucci L, Tamburi F, Cardillo C, Schinzari F, Rovella V, Nisticò S, Bennardo L, Di Daniele N, Tesauro M. Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases. Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419827154. doi: 10.1177/2058738419827154. PMID: 30706739; PMCID: PMC6360470.
- Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015 Jun 6;385(9984):2264-2271. doi: 10.1016/S0140-6736(14)61730-X. Epub 2015 Mar 4. PMID: 25748612; PMCID: PMC4608367.
- Ikonomidis I, Kadoglou NN, Tritakis V, Paraskevaidis I, Dimas K, Trivilou P, Papadakis I, Tzortzis S, Triantafyllidi H, Parissis J, Anastasiou-Nana M, Lekakis J. Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease. Atherosclerosis. 2014 May;234(1):34-41. doi: 10.1016/j.atherosclerosis.2014.02.004. Epub 2014 Feb 18. PMID: 24594367.
- Ikonomidis I, Kadoglou NN, Tritakis V, Paraskevaidis I, Dimas K, Trivilou P, Papadakis I, Tzortzis S, Triantafyllidi H, Parissis J, Anastasiou-Nana M, Lekakis J. Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease. Atherosclerosis. 2014 May;234(1):34-41. doi: 10.1016/j.atherosclerosis.2014.02.004. Epub 2014 Feb 18. PMID: 24594367.
- Yu J, Zhang RF, Mao YL. Cerebellar fastigial nucleus electrostimulation attenuates inflammation in a Post-Infarction rat model by activating cholinergic anti-inflammatory pathway. Neurosci Lett. 2022 Sep 25;788:136860. doi: 10.1016/j.neulet.2022.136860. Epub 2022 Aug 27. PMID: 36041546.
- Golanov EV, Zhou P. Neurogenic neuroprotection. Cell Mol Neurobiol. 2003 Oct;23(4-5):651-63. doi: 10.1023/a:1025088516742. PMID: 14514022.
- Qiaoying Z, Xiaogang Z, Zuo L, Quan H, Wenwu Z, Lina Z. Clinic study on treatment of cardiac arrhythmia by fastigial nucleus stimulation. Journal of Chongqing Medical University. 2010;35(6):905-907.
- Nguyen MT, Fernando S, Schwarz N, Tan JT, Bursill CA, Psaltis PJ. Inflammation as a Therapeutic Target in Atherosclerosis. J Clin Med. 2019 Jul 26;8(8):1109. doi: 10.3390/jcm8081109. PMID: 31357404; PMCID: PMC6722844.
- Liu B, Zhang Y, Jiang Y, Li L, Li C, Li J. Electrical stimulation of cerebellar fastigial nucleus protects against cerebral ischemic injury by PPARγ upregulation. Neurol Res. 2017 Jan;39(1):23-29. doi: 10.1080/01616412.2016.1251710. Epub 2016 Nov 7. PMID: 27819182.
- Xia D, Sui R, Min L, Zhang L, Zhang Z. Fastigial nucleus stimulation ameliorates cognitive impairment via modulating autophagy and inflammasomes activation in a rat model of vascular dementia. J Cell Biochem. 2019 Apr;120(4):5108-5117. doi: 10.1002/jcb.27787. Epub 2018 Dec 14. PMID: 30552710.
- Wang M, Guo J, Dong LN, Wang JP. Cerebellar Fastigial Nucleus Stimulation in a Chronic Unpredictable Mild Stress Rat Model Reduces Post-Stroke Depression by Suppressing Brain Inflammation via the microRNA-29c/TNFRSF1A Signaling Pathway. Med Sci Monit. 2019 Jul 28;25:5594-5605. doi: 10.12659/MSM.911835. PMID: 31352465; PMCID: PMC6683727.
